GPCR Biosensors receive RSRI Award

Biopharmaceutical company Domain Therapeuticsa developer of drug candidates targeting G Protein-Coupled Receptors (GPCR) in neurology, oncology and rare diseases, has received, together with Pr Michel Bouvier, the RSRI award from the Association des Directeurs de Recherche Industrielle du Quebec (ADRIQ) at the Innovation Prize gala.

 Created in 2019, this award, presented by the nine Regroupement Sectoriel de Recherche Industrielle in Quebec (RSRIs), illustrates the strength of the bonds between the research community and industry. It also highlights the significant impact of a collaborative research project on the Quebec economy through the creation of new jobs.

 The technology, in-licensed by Domain Therapeutics in 2013 from University of Montreal, benefited from a €1.8M (US$2M) investment from the Consortium Québécois sur la Découverte Du Médicament (CQDM) over three years and the expertise of a consortium of Canadian researchers: Pr Michel Bouvier and Dr Christian Le Gouill (IRIC – Institute for Research in Immunology and Cancer at the University of Montreal), Pr Graciela Pineyro (research center, Sainte-Justine Hospital), Pr Stéphane Laporte and Pr Terry Hebert (McGill University), and Pr Richard Leduc (Sherbrooke University).

Developing the potential uses of this technology through its Montreal based-subsidiary Domain Therapeutics NA Inc. (DTNA), the company designs biosensors for GPCR-acting treatments and applications to other membrane receptors.

“We are honoured to be awarded this prize, recognising the successful collaboration between our company and the consortium led by Pr Michel Bouvier,” said Pascal Neuville, CEO, Domain Therapeutics. “This prize highlights the quality of research in Quebec and particularly in Montreal. Domain Therapeutics is very pleased to have turned such groundbreaking innovation into a value-creation business.”